Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nano-EGCG
- Development stage
- Preclinical
- Lead developer
- University of Wisconsin–Madison
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral
01
Overview
nano-EGCG is a nanoparticle formulation of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) encapsulated in a chitosan polymer. Developed to overcome the poor oral bioavailability and rapid metabolism of free EGCG, this "nanochemoprevention" approach utilizes the naturally occurring polymer chitosan to provide sustained release and enhanced stability. In preclinical models of human melanoma, nano-EGCG has demonstrated significantly higher potency than non-encapsulated EGCG, inducing apoptosis through the modulation of the Bax/Bcl-2 ratio, activation of caspases, and induction of cyclin-dependent kinase inhibitors p21 and p27. It has shown efficacy in inhibiting tumor growth in mouse xenograft models at doses ten-fold lower than free EGCG.
- Other names
- chitosan-encapsulated EGCG(-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles
02
Targets
CDKN1B (Transmembrane emp24 domain-containing protein 7)CASP3 (Caspase-3)BAX (Apoptosis regulator BAX)CASP9 (Caspase-9)
Beyond the preview
Go deeper on nano-EGCG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nano-EGCG.